Qingwen Zhili Powder Veterinary Grade API is distributed as a non-sterile, botanical-derived powder intended for further processing into tablets, injections, capsules, powders, granules, premix, and solutions. The manufacturer assigns model designations QWZL-V-API-40, QWZL-V-API-80, and QWZL-V-API-120; these model fields correspond to nominal sieve cuts of 40 mesh, 80 mesh, and 120 mesh, where 80 mesh equates to an aperture of approximately 177 µm. The model designation is not a pharmacopoeial identity; it is a supply-chain and process-fit code. The powder is not sterile in its standard presentation and is not intended for direct injection without subsequent aseptic dissolution, filtration, and terminal sterilization or validated equivalent treatment. Its release dossier should be read through the receiving dosage-form context: a specification that is acceptable for oral granules may be insufficient for injectable solutions because of sub-visible particulate and endotoxin requirements.

The material is supplied in heat-sealed aluminium-foil laminate bags with desiccant and oxygen absorber provisions where required; packaging selection is driven by moisture gain below 60% relative humidity sensitivity. The product should be dispensed in controlled environments because hygroscopic botanical powders can gain surface moisture during open handling, altering flow function coefficient and compromising tablet weight control. The incoming release should include confirmation of appearance, particle-size distribution, loss on drying, total ash, microbial enumeration, and marker assay; these parameters are not interchangeable with those of purified extract or synthetic chemical APIs.

What Release Specifications Govern Identity and Purity?

Release testing for this veterinary-grade powder follows a botanically derived matrix profile rather than a single-assay chemical entity. Identification is confirmed by high-performance liquid chromatography fingerprinting with specific marker compounds together with thin-layer chromatography against a retained reference standard. The assay strategy is in line with monographs of the Chinese Veterinary Pharmacopoeia 2020 where applicable, though the exact marker acceptance range is dossier-specific and not publicly transferable. Loss on drying is measured by USP <731> or Ph. Eur. 2.2.32; a common pharmacopoeial expectation for non-sterile botanical powder is not more than 5.0%, but the approved veterinary product specification may be lower. Total ash and acid-insoluble ash are determined by USP <561>. Heavy metals are controlled by risk-based limits aligned with the target animal species, the intended feeding duration, and the receiving regulatory region; published data for this specific configuration is limited in the public domain, so the actual release limit is defined in the registration dossier. Microbial enumeration is evaluated according to USP <2021> and Ph. Eur. 5.1.4, with absence of specified organisms assessed by USP <2022> or regional equivalent. For any injectable claim, bacterial endotoxin testing per USP <85> or Ph. Eur. 2.6.14 is mandatory.

Direct compression of this API on a rotary tablet press requires careful characterization of flow function coefficient, bulk density, and particle-size distribution. Botanical powders of this type can exhibit cohesive flow because of irregular particle morphology and residual moisture; if the flow function coefficient is below 4, the material is classified as cohesive and is unlikely to maintain die-fill consistency on high-speed press runs. When pre-compression and forced feeder operation alone do not stabilize die filling, dry granulation by roller compaction at roll pressure between 4 MPa and 8 MPa or low-shear wet granulation with purified water or a binder solution is used. At production scale, a single-station or rotary tablet press with pre-compression rollers should be equipped with compression force monitoring; tablet hardness, friability, and dissolution are tested against the approved veterinary product specification. Granulation endpoint control should not rely solely on visual assessment; an in-process moisture balance or near-infrared moisture probe with a target range tied to rapid loss-on-drying is recommended. Lubrication with magnesium stearate at 0.5–1.5% w/w may be required, but over-lubrication above 2.0% w/w can reduce tablet tensile strength. If the powder is milled to 120 mesh for capsule filling, the increase in surface area can raise hygroscopic uptake; therefore, closed-transfer and conditioned-air systems are specified.

Capsule Filling and Granule Processing Differences Across Models

Low-shear wet granulation, dry granulation, and capsule filling impose different particle-size and moisture constraints on the same API powder. For capsule filling on an automatic dosing-disc or tamping-pin machine, a model grade with smaller nominal particle size, QWZL-V-API-80 or QWZL-V-API-120, is usually selected because lower fill weight variability can be achieved when the median particle size is reduced. However, fine powders with high cohesion can cause stagnation in the powder bed; adding a glidant such as colloidal silicon dioxide at 0.1–1.0% w/w is typical, although the exact level should be optimized by shear-cell testing under ASTM D7891. For granules intended for oral solutions or top-dress powders, wet granulation requires a defined liquid-to-solid ratio; over-wetting produces hard, poorly dispersible granules, while under-wetting creates friable granules that segregate during conveying. Fluid-bed drying at inlet air temperature 50–60 °C is common for botanical granulations, with product temperature held below the degradation threshold of the marker constituents. If the marker compound is thermally labile, vacuum drying or low-humidity dehumidified-air drying should be evaluated. The granulation process also affects dissolution performance; granules that are too dense may show slower release in oral powders. For premix and dry powder applications, a fitted batch blender such as a twin-shell V-blender or bin blender with an intensifier bar is used, and blend uniformity should be tested according to USP <905> or Ph. Eur. 2.9.40 as applicable to the finished veterinary product.

When Qingwen Zhili Powder Is Intended for Injectable Solutions

Terminal sterilization after aseptic dissolution or suspension is the standard industrial route for injectable preparations derived from this powder. The powder is not sterile; a solution prepared from it must pass through a sterilizing-grade filter of 0.22 µm or 0.20 µm rating before filling. The dissolution step should use high-shear dispersion because the botanical matrix contains polysaccharides and insoluble minerals that can form coarse dispersions. After dissolution, filtration load should be monitored; if filter blockage occurs before the intended batch volume is reached, a pre-filtration step with depth filtration or a larger-area capsule filter is required. Sub-visible particulate matter in the finished solution must comply with USP <788> or Ph. Eur. 2.9.19, and bacterial endotoxins must comply with the relevant species-specific limit per USP <85> or Ph. Eur. 2.6.14. Terminal steam sterilization at 121 °C for at least 15 min may be used only if the formulated solution is thermostable; otherwise, validated aseptic filtration is required. The standard powder has not been depyrogenated; therefore, injectable grades require an additional depyrogenation or endotoxin-controlled manufacturing claim from the supplier. The production record should document that the solution is clear or opalescent within specification before filtration, because residual insoluble ash can increase particulate matter beyond acceptance limits. Published data for this specific injectable configuration is limited; process developers should perform filter compatibility and extractable/leachable studies under current veterinary quality guidance rather than relying on tablet-grade data.

In medicated feed premix operations, volumetric metering of Qingwen Zhili Powder is not recommended unless feeder calibration is repeated after each lot because bulk density varies with particle-size distribution and moisture. Loss-in-weight feeders with mass-based control are preferred, and the final mix should be validated for carryover and cross-contamination under the current EMA/CVMP quality guidelines for veterinary medicinal products. Mixer uniformity studies should be performed in the actual production blender; a coefficient of variation of not more than 5.0% for the marker or active component is a common acceptance criterion, but the registered specification may differ. For oral powders and granules, the material is often dry-blended with lactose or dextrose carriers after geometric dilution; geometric dilution is not a computational substitute for mixer validation. The powder should be stored in closed containers at relative humidity below 60%; if storage exceeds the moisture-protective barrier, re-drying may be required before release for use. Use in drinking water solutions requires additional consideration of sedimentation, nozzle clogging, and pH-dependent solubility; a 100-mesh or 120-mesh grade may reduce settling but does not guarantee solubility because fibrous botanical components remain suspended.

Unlike purified extract concentrates, the full-powder API retains matrix polysaccharides, mineral ash, and fiber. This full-matrix character increases solution viscosity and filtration load during injectable preparation, but it also preserves broader phytoconstituent profiles that may differ from isolated marker therapy. In tablet and capsule routes, the product usually requires dry granulation or wet granulation rather than direct compression because of cohesive flow and low bulk density; synthetic chemical APIs may not require these processing steps. For premix and feed, the powder is more likely to segregate in transport if the particle-size distribution is wide; final blending and transport validation under EMA/CVMP quality guidance is required. The material also presents broader microbial enumeration risk than a synthetic API; incoming release must verify Ph. Eur. 5.1.4 or equivalent. These differences make it unsuitable as a drop-in replacement for a purified chemical API without re-qualification of the entire downstream process.